Sign In
Buy INO
$0.677
+0.0210 (+3.20%)
At Close: Jul 31, 2026
INOVIO to Report First Quarter Financial Results on May 13, 2026
04:05pm, Friday, 01'st May 2026
PLYMOUTH MEETING, Pa., May 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-relate
Vertex Gears Up to Report Q1 Earnings: What Investors Can Expect
01:36pm, Tuesday, 28'th Apr 2026
VRTX heads into Q1 earnings with Trikafta demand, rising Alyftrek sales, and Casgevy and Journavx sales in focus ahead of the May 4 report.
Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers – INO
03:46pm, Tuesday, 07'th Apr 2026
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) a
NEW YORK, April 7, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023
BENSALEM, Pa. , April 07, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-trade
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) betwe
NEW YORK--(BUSINESS WIRE)---- $INO #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Inovio Pharmaceuticals, Inc. (“Inovio” or t
NEW YORK, April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO). Shareholders who purchased shares of INO during th
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Inovio (INO) To Contact Him Directly To Discuss Their Options
New York, New York--(Newsfile Corp. - April 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between Oc
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming April 7, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsui
Bronstein, Gewirtz & Grossman LLC Urges Inovio Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Monday, 06'th Apr 2026
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Inovio P
Portnoy Law Firm Announces Class Action on Behalf of Inovio Pharmaceuticals, Inc. Investors
10:50am, Monday, 06'th Apr 2026
LOS ANGELES, April 06, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Inovio Pharmaceuticals, Inc., (“Inovio” or the "Company") (NASDAQ: INO) investors of a class action on behalf of inves
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options If you purchased or acquired
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
09:30am, Monday, 06'th Apr 2026
LOS ANGELES, April 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inovio Pharmaceuticals, Inc. (�
